1. WHO. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2014.

2. koohgard giulani R, ghasemi A. Factors Associated with Delayed Diagnosis of Tuberculosis in Patients Referred to Razi Hospital in Rasht, 2023. Iran J Health Res Dev 2026; 4 (1) :24-33. [DOI:10.66224/jhrd.4.1.24]

3. Huang K, Hu C-Y, Yang X-Y, Zhang Y, Wang X-Q, Zhang K-D, et al. Contributions of ambient temperature and relative humidity to the risk of tuberculosis admissions: a multicity study in Central China. Science of the Total Environment. 2022;838:156272. [DOI:10.1016/j.scitotenv.2022.156272] [PMID]

4. Khurana AK, Aggarwal D. The (in) significance of TB and COVID-19 co-infection. European Respiratory Journal. 2020;56(2):2002105. [DOI:10.1183/13993003.02105-2020] [PMID] [PMCID]

5. Visca D, Ong C, Tiberi S, Centis R, D'ambrosio L, Chen B, et al. Tuberculosis and COVID-19 interaction: a review of biological, clinical and public health effects. Pulmonology. 2021;27(2):151-65. [DOI:10.1016/j.pulmoe.2020.12.012] [PMID]

6. Menzies NA, Quaife M, Allwood BW, Byrne AL, Coussens AK, Harries AD, et al. Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. The Lancet Global Health. 2021;9(12):e1679-e87. [DOI:10.1016/S2214-109X(21)00367-3] [PMID] [PMCID]

7. Bagcchi S. WHO's global tuberculosis report 2022. The Lancet Microbe. 2023;4(1):e20. [DOI:10.1016/S2666-5247(22)00359-7] [PMID]

8. Ledesma JR, Ma J, Zhang M, Basting AV, Chu HT, Vongpradith A, et al. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet infectious diseases. 2024;24(7):698-725. [DOI:10.1016/S1473-3099(24)00007-0] [PMID] [PMCID]

9. Murray CJ. Findings from the global burden of disease study 2021. The Lancet. 2024;403(10440):2259-62. [DOI:10.1016/S0140-6736(24)00769-4] [PMID]

10. Mathers CD, Vos T, Lopez AD, Salomon J, Ezzati M. National burden of disease studies: a practical guide. Geneva: World Health Organization. 2001.

11. Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1859-922. [DOI:10.1016/S0140-6736(18)32335-3] [PMID]

12. Allwood BW, Van Der Zalm M, Amaral A, Byrne A, Datta S, Egere U, et al. Post-tuberculosis lung health: perspectives from the First International Symposium. The International Journal of Tuberculosis and Lung Disease. 2020;24(8):820-8. [DOI:10.5588/ijtld.20.0067] [PMID]

13. Collaborators GCRD. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet Respiratory Medicine. 2017;5(9):691. [DOI:10.1016/S2213-2600(17)30293-X] [PMID]

14. Bostani M, Dehghani M, Taghipour A, Raufi F, Bostani B. Adherence of Physicians to the National Tuberculosis Control Program (DOTS Strategy) and associated factors in Birjand City. Iran J Health Res Dev 2026; 4 (2) :94-106 [DOI:10.66224/jhrd.4.2.94]

15. Meghji J, Gregorius S, Madan J, Chitimbe F, Thomson R, Rylance J, et al. The long term effect of pulmonary tuberculosis on income and employment in a low income, urban setting. Thorax. 2021;76(4):387-95. [DOI:10.1136/thoraxjnl-2020-215338] [PMID] [PMCID]

16. Duong M, Islam S, Rangarajan S, Leong D, Kurmi O, Teo K, et al. Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study. The Lancet Global Health. 2019;7(5):e613-e23. [DOI:10.1016/S2214-109X(19)30070-1] [PMID]

17. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO's new end TB strategy. The Lancet. 2015;385(9979):1799-801. [DOI:10.1016/S0140-6736(15)60570-0] [PMID]

18. Lange C, Chesov D, Heyckendorf J, Leung CC, Udwadia Z, Dheda K. Drug‐resistant tuberculosis: an update on disease burden, diagnosis and treatment. Respirology. 2018;23(7):656-73. [DOI:10.1111/resp.13304] [PMID]

19. Li X, Li Y, Guo L, Chen Y, Wang G, Zhang H. Tuberculosis incidence, deaths and disability-adjusted life years in children and adolescence, 1990-2021: Results from the Global Burden of Disease Study 2021. PloS one. 2025;20(3):e0317880. [DOI:10.1371/journal.pone.0317880] [PMID] [PMCID]

20. Cui K, Zhao X, Liu W, Bai L. Global, regional, and national burden and trends of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis in adolescents and adults aged 15-49 years from 2010 to 2021: insights from the global burden of disease study 2021. BMC medicine. 2025;23(1):445. [DOI:10.1186/s12916-025-04269-7] [PMID] [PMCID]

21. Kaffash A, Shobeiri SS, Pouraslan E, Kazemzadeh A, Mohammadi FD, Ghazal N, et al. The epidemiology of tuberculosis infection and the Human Development Index (HDI) in Iran between 1990-2021: secondary analysis of the global burden of disease. BMC Infectious Diseases. 2026;26(1):995. [DOI:10.1186/s12879-026-13148-2] [PMID] [PMCID]

22. Baghdadi S. Situational analysis of tuberculosis control programs in the Eastern Mediterranean Region: Gaps and solutions. International Journal of Mycobacteriology. 2016;5:S14. [DOI:10.1016/j.ijmyco.2016.10.002] [PMID]

23. Yuanyuan L, Jingjing X, Shutao L, Dongdong S, Tian Z, Puxuan L, et al. 2024 WHO tuberculosis report: key data analysis for China and the global world. Electronic Journal of Emerging Infectious Diseases. 2025;9(6):92.

24. Kiani B, Raouf Rahmati A, Bergquist R, Hashtarkhani S, Firouraghi N, Bagheri N, et al. Spatio-temporal epidemiology of the tuberculosis incidence rate in Iran 2008 to 2018. BMC Public Health. 2021;21(1):1093. [DOI:10.1186/s12889-021-11157-1] [PMID] [PMCID]

25. Khazae S, Ayubi E, Mansournia MA, Rafiemanesh H. Trend of some Tuberculosis Indices in Iran during 25 yr Period (1990-2014). Journal of research in health sciences. 2016;16(3):141.

26. Chen Z, Wang T, Du J, Sun L, Wang G, Ni R, et al. Decoding the WHO global tuberculosis report 2024: a critical analysis of global and Chinese key data. Zoonoses. 2025;5(1):999. [DOI:10.15212/ZOONOSES-2024-0061]

27. Khademi F, Sahebkar A. An updated systematic review and meta-analysis on Mycobacterium tuberculosis antibiotic resistance in Iran (2013-2020). Iranian Journal of Basic Medical Sciences. 2021;24(4):428.

28. Nasiri MJ, Heidary M, Goudarzi H, Tabarsi P. Trends in multidrug-resistant tuberculosis in Tehran, Iran: an analysis of published data. GMS hygiene and infection control. 2019;14:Doc11.

29. Ayoubi S, Farnia P, Farnia P, Ghanavi J, Velayati AA. Prevalence and temporal trends of multidrug-resistant tuberculosis in Iran from 1981 to 2023: a systematic review and meta-analysis. The International Journal of Mycobacteriology. 2024;13(3):320-30. [DOI:10.4103/ijmy.ijmy_162_24] [PMID]

30. Daneshi S, Mehni EB, Kamali M, Barfar E, Barahouei FB, Hushmandi K, et al. Prevalence and contributing factors of drug-resistant tuberculosis (DR-TB) in iran: a systematic review. BMC Infectious Diseases. 2025;25(1):1004. [DOI:10.1186/s12879-025-11439-8] [PMID] [PMCID]

31. Moradinazar M, Afshar ZM, Ramazani U, Shakiba M, Shirvani M, Darvishi S. Epidemiological features of tuberculosis in the Middle East and North Africa from 1990 to 2019: results from the global burden of disease Study 2019. African Health Sciences. 2023;23(3):366. [DOI:10.4314/ahs.v23i3.43] [PMID] [PMCID]

32. Bai W, Ameyaw EK. Global, regional and national trends in tuberculosis incidence and main risk factors: a study using data from 2000 to 2021. BMC Public Health. 2024;24(1):12. [DOI:10.1186/s12889-023-17495-6] [PMID] [PMCID]